Medicine and Dentistry
Thyroid Cancer
100%
Neoplasm
93%
Diseases
77%
Malignant Neoplasm
73%
Thyroid Medullary Carcinoma
67%
Pheochromocytoma
64%
Differentiated Thyroid Cancer
55%
Cancer
53%
Paraganglioma
48%
Thyroid Gland
46%
Adrenal Cortex Carcinoma
45%
Radioactive Iodine
40%
Metastatic Carcinoma
39%
Anaplastic Thyroid Carcinoma
37%
Surgery
34%
Overall Survival
32%
Papillary Thyroid Cancer
31%
Thyroid Carcinoma
27%
Clinical Trial
27%
Targeted Therapy
25%
Radiation Therapy
23%
Recurrent Disease
21%
Thyroidectomy
18%
Proto Oncogene
17%
Tyrosine-Kinase Inhibitor
16%
Adverse Event
16%
Diagnosis
16%
Lenvatinib
15%
Neck
15%
Multiple Endocrine Neoplasia Type 2
15%
Progression Free Survival
15%
Parathyroid Carcinoma
15%
Multiple Endocrine Neoplasia Type I
15%
Cancer Therapy
15%
Systemic Therapy
14%
Thyroid Nodule
14%
Distant Metastasis
13%
Fine-Needle Aspiration
13%
Immunotherapy
13%
Calcitonin
12%
Genetic Screening
12%
Adrenalectomy
12%
Multiple Endocrine Neoplasia
12%
Iodine 131
11%
Hypercalcaemia
11%
Phosphotransferase Inhibitor
11%
Biological Marker
11%
Bone Metastasis
11%
Immune Checkpoint Inhibitor
11%
Osteolysis
11%
Breast Cancer
11%
Endocrine Tumor
11%
Pediatrics
10%
Pembrolizumab
10%
Primary Tumor
10%
Oncology
10%
Primary Hyperparathyroidism
10%
Exon
10%
Cabozantinib
9%
Hazard Ratio
9%
Cancer Cell
9%
Cushing Syndrome
9%
Prevalence
9%
Thyroid Hormone
9%
Corticotropin
9%
Patient Referral
8%
Computer Assisted Tomography
8%
Neuroendocrine Tumor
8%
Echography
8%
Phosphotransferase
8%
Germ Cell
8%
Combination Therapy
7%
Diabetes
7%
Arm
7%
Disease Specific Survival
7%
Clinician
7%
Hypothyroidism
7%
Osteoporosis
7%
Germline Mutation
7%
Immunity
7%
Adrenal Adenoma
7%
Gene Mutation
7%
Systematic Review
7%
Genetic Transfection
7%
Codon
7%
Bisphosphonate
7%
Thyrotropin
6%
Parathyroid Hormone
6%
Endocrine Disease
6%
Hyperglycemia
6%
Quality of Life
6%
Melanoma
6%
Hydrocortisone
6%
Retrospective Study
6%
Genetic Disorder
6%
Carcinogenesis
6%
Catecholamine
6%
Cell Signaling Pathway
6%
Adrenal Gland
6%
Disease Free Survival
6%
Keyphrases
Anaplastic Thyroid Cancer
45%
Thyroid Cancer
45%
Medullary Thyroid Carcinoma
45%
Medullary Thyroid Cancer
35%
Tumor
33%
Adrenocortical Carcinoma
29%
Pheochromocytoma
28%
Differentiated Thyroid Cancer
27%
Overall Survival
22%
Multiple Endocrine Neoplasia Type 2 (MEN2)
21%
Thyroid Carcinoma
20%
Clinical Trials
18%
Confidence Interval
18%
Metastatic Paraganglioma
16%
Phase II Trial
16%
Metastatic Pheochromocytoma
16%
Targeted Therapy
15%
Paraganglioma
15%
Calcitonin
14%
Differentiated Thyroid Carcinoma
14%
Metastatic Disease
14%
Cabozantinib
13%
Adverse Events
13%
Distant Metastasis
13%
RET Proto-oncogene
12%
Papillary Thyroid Carcinoma
12%
Multikinase Inhibitor
12%
Multiple Endocrine Neoplasia Type 1 (MEN1)
12%
Radioactive Iodine
12%
Pembrolizumab
12%
Malignancy
11%
BRAF V600E
11%
Systemic Therapy
11%
Bone Metastasis
11%
Lenvatinib
10%
Sorafenib
10%
Progression-free Survival
10%
Kinase Inhibitor
10%
Metastatic Thyroid Cancer
9%
Thyroid Patients
9%
Sporadic Medullary Thyroid Carcinoma
9%
Parathyroid Carcinoma
9%
Clinical Outcomes
9%
Advanced or Metastatic
9%
Tyrosine Kinase Inhibitor
9%
Metastasis
9%
Papillary Thyroid Cancer
9%
Sympathetic Paraganglioma
8%
MD Anderson Cancer Center
8%
Oncology
8%
Immune Checkpoint Inhibitors
8%
Surgical Resection
8%
Advanced Thyroid Cancer
8%
Radioiodine-refractory Differentiated Thyroid Cancer
8%
Vandetanib
8%
Adrenal Mass
8%
Phase II Study
8%
Malignant Pheochromocytoma
8%
Partial Response
8%
Adrenal Cortical Carcinoma
7%
Immune-related Adverse Events
7%
Exon
7%
Trametinib
7%
Osteoporosis
7%
Malignant Paraganglioma
7%
Chemotherapy
6%
Stable Disease
6%
Radiation Therapy
6%
Treatment Options
6%
Center Experience
6%
Selpercatinib
6%
Patient Management
6%
Dabrafenib
6%
Iodine-131 (131I)
6%
Consensus Statement
6%
Primary Tumor
6%
BRAF Inhibitor (BRAFi)
6%
Median Progression-free Survival
6%
High Risk
6%
Thyroid Nodule
6%
Hereditary Medullary Thyroid Carcinoma
6%
Hypertension
6%
Hypercalcemia
6%
Melanoma
5%
Calcitonin Gene-related Peptide
5%
Clinical Benefit
5%
Endocrine Tumors
5%
Adrenal Adenoma
5%
Hypothyroidism
5%
Neuroendocrine Tumor
5%
Objective Response Rate
5%
Recent Advances
5%
Cancer Center
5%
Overexpression
5%
Locally Advanced
5%
Hazard Ratio
5%
In Cancer
5%
PAK1
5%
Median Overall Survival
5%
Metastatic Pheochromocytoma/paraganglioma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Cancer
95%
Malignant Neoplasm
61%
Neoplasm
60%
Diseases
54%
Differentiated Thyroid Cancer
52%
Thyroid Medullary Carcinoma
44%
Anaplastic Thyroid Carcinoma
39%
Radioactive Iodine
34%
Pheochromocytoma
28%
Overall Survival
28%
Clinical Trial
26%
Paraganglioma
25%
Protein Tyrosine Kinase Inhibitor
24%
Thyroid Carcinoma
24%
Adverse Event
22%
Thyroid Papillary Carcinoma
20%
Progression Free Survival
19%
Calcitonin
16%
Adrenal Cortex Carcinoma
16%
Chemotherapy
15%
Phosphotransferase Inhibitor
15%
Cabozantinib
15%
Metastasis
13%
Hypothyroidism
13%
Sorafenib
12%
Thyrotropin
10%
Combination Therapy
10%
Solid Malignant Neoplasm
10%
Vandetanib
10%
Bisphosphonic Acid Derivative
9%
Thyroid Hormone
9%
Carcinogenesis
9%
Lenvatinib
9%
Dabrafenib
9%
Phosphotransferase
8%
Trametinib
8%
Recurrent Disease
8%
Biological Marker
8%
Receptor
7%
Thyroglobulin
7%
Pembrolizumab
7%
Placebo
7%
Tumor Growth
7%
Epidermal Growth Factor Receptor
6%
Breast Cancer
6%
Disease Exacerbation
6%
Thyroid Nodule
6%
Primary Tumor
6%
Denosumab
6%
Immunotherapy
6%
Side Effect
6%
Hypercalcaemia
6%
Iodine-131
6%
Phase II Trials
6%
Immune Checkpoint Inhibitor
6%
Sunitinib
6%
Prevalence
5%
Dexamethasone
5%
Jaw Osteonecrosis
5%
Multiple Endocrine Neoplasia Type 2
5%
Hyperglycemia
5%
Protein Tyrosine Kinase
5%
Carcinoma
5%
Vasculotropin Receptor
5%
Distant Metastasis
5%
Monotherapy
5%
Leukemia
5%
Vemurafenib
5%
Endocrine Tumor
5%